title: [Should we add antiplatelet therapy to oral anticoagulation in patients with atrial fibrillation and vascular disease? Review of available evidence].
abstract: Current recommendation is to add antiplatelet drug to oral anticoagulation in patients with atrial fibrillation (AF) and vascular disease. However, it is debatable to join both antithrombotic drugs in stable vascular disease.
authors.affiliation: Servicio de Cardiología, Hospital Universitario Virgen de la Arrixaca, Murcia, España.
authors.forename: José Manuel
authors.initials: JM
authors.lastname: Andreu
authors.forename: Vanessa
authors.initials: V
authors.lastname: Roldán
authors.forename: Miguel
authors.initials: M
authors.lastname: García-Navarro
authors.forename: Juan Antonio
authors.initials: JA
authors.lastname: Ruipérez
authors.forename: Mariano
authors.initials: M
authors.lastname: Valdés
authors.forename: Francisco
authors.initials: F
authors.lastname: Marín
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D014652:Vascular Diseases / Q000150:complications*
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors